HYPERION DEFI, INC.

Hyperion DEFI, Inc.

Biotechnology • Healthcare • New York, NY, United States • HYPD (NCM)

Hyperion DeFi, Inc., an ophthalmic technology company, engages in development and commercialization of ophthalmic solutions in the United States. The company offers Optejet, a topical ophthalmic medication dispensing platform services. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi; and agreement with Formosa Pharmaceuticals. Inc. for Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S. The company was formerly known as Eyenovia, Inc. and changed its name to Hyperion DeFi, Inc. in July 2025. Hyperion DeFi, Inc. was founded in 2014 and is based in New York, New York.

917 289 1117 295 Madison Avenue, New York, NY 10017, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Chardan Capital initiates Hyperion DeFi stock with Buy rating, $7.75 target - Investing.com
Investing.com • Dec 24
Chardan Capital Initiates Coverage of Hyperion DeFi (HYPD) with Buy Recommendation - Nasdaq
Nasdaq • Dec 24
Hyperion DeFi (HYPD) Gets a Buy from Chardan Capital - The Globe and Mail
The Globe and Mail • Dec 25
Top Hyperion DeFi Insider Quietly Makes a Bold Move on the Stock - TipRanks
TipRanks • Dec 23
Hyperion DeFi Inc (HYPD) Q3 2025 Earnings Call Highlights: Record Income and Strategic ... - Yahoo Finance
Yahoo Finance • Nov 13

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has HYPERION DEFI, INC. had layoffs?
No layoff events have been recorded for HYPERION DEFI, INC. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does HYPERION DEFI, INC. have?
HYPERION DEFI, INC. has approximately 13 employees.
What industry is HYPERION DEFI, INC. in?
HYPERION DEFI, INC. operates in the Biotechnology industry, within the Healthcare sector.
Is HYPERION DEFI, INC. a publicly traded company?
Yes, HYPERION DEFI, INC. is publicly traded under the ticker symbol HYPD on the NCM. The company has a market capitalization of approximately $0.03 billion.
Where is HYPERION DEFI, INC. headquartered?
HYPERION DEFI, INC. is headquartered in New York, NY, United States at 295 Madison Avenue, New York, NY 10017, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.